41P Progression after chemo-IO and durvalumab in stage III non-small cell lung cancer (NSCLC): What should be the next line? Real-world study

NSCLC patients diagnosed with unresectable stage III are treated concurrent chemotherapy-radiotherapy (chemo-RT) followed by durvalumab (PD-L1-inhibitor). No standard-of-care exists for progressing on this regimen. In study we aimed to evaluate therapies administered these patients. Multi-center, academic-initiated retrospective of consecutive and chemo-RT at-least 1 dose between March 2016 October 2020. Data was collected from patients' electronic charts. Responses were assessed reporting oncologist. 116 identified in databases 3 academic oncology centers-Rambam, Sheba Tel-Aviv-Sourasky; median follow-up time 15 months ( range 1-46), age 66, 74% males, 54% adenocarcinoma. Radiation 60-66GY 92% A 14 cycles (range 1-40); 31.9% completed year treatment. 78 (67.2% the cohort) progressed or after durvalumab, 21% brain metastases; 51 metastatic disease. Median progression initiation 7.1 (range-0.1-29.1), 27 (53%) combined chemotherapy immune-checkpoint inhibitors (chemo-IO), 16 (31%) alone, 4 (8%) IO alone. time-on-treatment chemo-IO 5.5 1.2-19.6), 4.9 (0.5-21.7; p- non-significant- NS), 2.4 alone (0.5-5.6). 79% had PR SD, compared 60% chemo (NS): PD. 37 (31.9% died. following there no significant difference response treatment vs.